FDA Approves First Therapy for Allergic Fungal Rhinosinusitis
Patients with allergic fungal rhinosinusitis now have a targeted biologic option.
-
By
-
Kathryn Wighton
-
February 25, 2026
-
-
1
Dupilumab is the first FDA-approved therapy for allergic fungal rhinosinusitis in patients aged 6 years and older.
-
2
The condition affects up to 8% of patients with chronic sinus inflammation and is characterized by thick mucus accumulation.
-
3
Dupilumab treatment improved sinus opacification, nasal polyp size, nasal congestion, and olfactory function over 52 weeks.
-
4
The therapy reduced the need for systemic corticosteroids and sinus surgery, and decreased sinus bone erosion.
-
5
Common adverse reactions to dupilumab include injection-site reactions, eosinophilia, insomnia, and toothache.
